Linezolid surveillance results for the United States (LEADER surveillance program 2014)

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2273-2280

  Flamm, Robert K ^a   Mendes, Rodrigo E ^a   Hogan, Patricia A ^b   Streit, Jennifer M ^a   Ross, James E ^a   Jonesa, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b PFIZER INC   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BACTERIAL PROTEIN; CEFTRIAXONE; CFR PROTEIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; GLYCINE; LEVOFLOXACIN; LINEZOLID; METICILLIN; OPTRA PROTEIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN V; QUINOLONE DERIVATIVE; RIBOSOMAL PROTEIN L22; RIBOSOMAL PROTEIN L4; RIBOSOME PROTEIN; RIBOSOME PROTEIN L3; RNA 23S; TEICOPLANIN; TETRACYCLINE; THREONINE; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL PNEUMONIA; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BLOODSTREAM INFECTION; BROTH DILUTION; CHILD; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DISEASE SURVEILLANCE; ENTEROCOCCUS; EPIDEMIOLOGICAL MONITORING; FEMALE; GENE MUTATION; GRAM POSITIVE BACTERIUM; HEALTH PROGRAM; HUMAN; LINEZOLID EXPERIENCE AND ACCURATE DETERMINATION OF RESISTANCE SURVEILLANCE PROGRAM; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VERY ELDERLY; YOUNG ADULT; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEALTH SURVEY; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; GENE EXPRESSION; HUMANS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MUTATION; PUBLIC HEALTH SURVEILLANCE; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 23S; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 84963753501     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02803-15     Document Type: Article

References (27)

1. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. 2005. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 49:5024-5032. http://dx.doi.org/10.1128/AAC.49.12.5024-5032.2005.
2. Draghi DC, Sheehan DF, Hogan P, Sahm DF. 2006. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn Microbiol Infect Dis 55:129-133. http://dx.doi.org/10.1016/j.diagmicrobio.2006.01.003.
3. Jones RN, Ross JE, Castanheira M, Mendes RE. 2008. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 62:416-426. http://dx.doi.org/10.1016/j.diagmicrobio.2008.10.010.
4. Farrell DJ, Mendes RE, Ross JE, Jones RN. 2009. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 65:392-403. http://dx.doi.org/10.1016/j.diagmicrobio.2009.10.011.
5. Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. 2011. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6, 414 clinical isolates from the United States (56 medical centers). Antimicrob Agents Chemother 55:3684-3690. http://dx.doi.org/10.1128/AAC.01729-10.
6. Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. 2012. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn Microbiol Infect Dis 74:54-61. http://dx.doi.org/10.1016/j.diagmicrobio.2012.05.012.
7. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. 2013. Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother 57:1077-1081. http://dx.doi.org/10.1128/AAC.02112-12.
8. Mendes RE, Flamm RK, Hogan PA, Ross JE, Jones RN. 2014. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States. Antimicrob Agents Chemother 58:1243-1247. http://dx.doi.org/10.1128/AAC.02112-13.
9. Flamm RK, Mendes RE, Hogan PA, Ross JE, Farrell DJ, Jones RN. 2015. In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. Diagn Microbiol Infect Dis 81:283-289. http://dx.doi.org/10.1016/j.diagmicrobio.2014.12.009.
10. Shinabarger D. 1999. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs 8:1195-1202. http://dx.doi.org/10.1517/13543784.8.8.1195.
11. Ford CW, Zurenko GE, Barbachyn MR. 2001. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord 1:181-199. http://dx.doi.org/10.2174/1568005014606099.
12. Diekema DJ, Jones RN. 2001. Oxazolidinone antibiotics. Lancet 358:1975-1982. http://dx.doi.org/10.1016/S0140-6736 (01) 06964-1.
13. Ippolito JA, Kanyo ZF, Wang D, Franceschi FJ, Moore PB, Steitz TA, Duffy EM. 2008. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem 51:3353-3356. http://dx.doi.org/10.1021/jm800379d.
14. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179. http://dx.doi.org/10.1016/S0140-6736 (00) 04376-2.
15. Mutnick AH, Enne V, Jones RN. 2003. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann Pharmacother 37:769-774. http://dx.doi.org/10.1345/aph.1C437.
16. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 52:2244-2246. http://dx.doi.org/10.1128/AAC.00231-08.
17. Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, Mankin AS. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 64:1506-1514. http://dx.doi.org/10.1111/j.1365-2958.2007.05744.x.
18. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. 2006. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimi-crob Agents Chemother 50:2500-2505. http://dx.doi.org/10.1128/AAC.00131-06.
19. Bonilla H, Huband MD, Seidel J, Schmidt H, Lescoe M, McCurdy SP, Lemmon MM, Brennan LA, Tait-Kamradt A, Puzniak L, Quinn JP. 2010. Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. Clin Infect Dis 51:796-800. http://dx.doi.org/10.1086/656281.
20. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Clinical and Laboratory Standards Institute. 2015. M100-S25. Performance standards for antimicrobial susceptibility testing: 25th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Clinical and Laboratory Standards Institute. 2015. M02-A12. Performance standards for antimicrobial disk susceptibility tests; 12th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Mendes RE, Deshpande LM, Farrell DJ, Spanu T, Fadda G, Jones RN. 2010. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother 65:2329-2335. http://dx.doi.org/10.1093/jac/dkq331.
24. Diaz L, Kiratisin P, Mendes R, Panesso D, Singh KV, Arias CA. 2012. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 56:3917-3922. http://dx.doi.org/10.1128/AAC.00419-12.
25. Mendes RE, Deshpande LM, Kim J, Myers D, Ross JE, Jones RN. 2012. Streptococcus sanguinis displaying a cross resistance phenotype to several ribosomal RNA targeting agents, including linezolid. Abstr 52nd Intersci Conf Antimicrob Agents Chemother, abstr C1-1343.
26. Wang Y, Lv Y, Cai J, Schwarz S, Cui L, Hu Z, Zhang R, Li J, Zhao Q, He T, Wang D, Wang Z, Shen Y, Li Y, Feßler AT, Wu C, Yu H, Deng X, Xia X, Shen J. 2015. A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. J Antimicrob Chemother 70:2182-2190. http://dx.doi.org/10.1093/jac/dkv116.
27. Pillar CM, Draghi DC, Sheehan DJ, Sahm DF. 2008. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER surveillance programs. Diagn Microbiol Infect Dis 60:221-224. http://dx.doi.org/10.1016/j.diagmicrobio.2007.08.007.